Viral vectors serve as essential tools in cellular therapy, particularly in introducing new or corrected genes into human cells. A prime example involves chimeric antigen receptor T (CAR T) cells utilizing lentivirus to integrate CAR genes into activated T cells. These vectors also have applications in treating genetic disorders like severe combined immunodeficiency disorder (SCID) and Wiskott-Aldrich syndrome. While lentiviral vectors excel in gene delivery and stable integration into host genomes, they pose certain health risks, including integration-mediated transformation and the potential generation of replication-competent lentivirus (RCL) capable of infecting non-target cells. Given these concerns, it is imperative for all cell-based products modified with lentiviral vectors and intended for patient use to undergo rigorous RCL testing prior to treatment.

Guidance Policy for Risk Assessment and RCL Testing

Lentiviral vectors can be safely developed under Biosafety Level 2 (BSL2) containment criteria if the following stipulations are met:

• The vector remains minimal, including only long terminal repeats (LTRs), packaging sequences, and does not incorporate coding gene sequences.
• A heterologous envelope is employed, avoiding HIV or SIV.
• Packaging plasmids lack sequences on the LTR that could recombine.
• Inserted genes do not code for oncogenes, their precursors, or highly toxic substances.

At Creative Biogene’s QVirus™ platform, reliable and affordable RCL testing is available for lentiviral vector stocks. With extensive experience in biosafety testing, we have successfully supported numerous regulatory submissions.

Assay Methods for Detecting Replication Competent Lentivirus

Cell-Based Assay
The primary method for RCL testing employs a cell-based assay using permissive cell lines that facilitate the expansion of low-level viruses, followed by viral protein detection. This process involves culturing vector-containing supernatant or vector-producing cells on the permissive cell line, allowing for virus amplification while diluting vector-associated reverse transcriptase (RT) activity. The culture supernatant from later passages undergoes analysis to detect retrovirus presence via the Product Enhanced Reverse Transcriptase (PERT) assay.

qPCR-Based Assays
QVirus™ Platform has engineered qPCR-based assays for the swift identification of RCL presence, ensuring timely infusion of the cell product. As reliance on rapid PCR testing increases, developing assays that are reproducible, accurate, and robustly sensitive while minimizing false positives becomes critical to upholding patient safety standards.

Lentiviral Vector Stocks Assays
Testing for RCL in lentiviral vector stocks focuses on monitoring p24 antigen expression in the culture media of transduced 293T cells. Serial passaging of transduced p24 cells amplifies any RCL present.